Zoetis Inc. (NYSE:ZTS) insider Roxanne Lagano sold 9,797 shares of Zoetis stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $50.43, for a total transaction of $494,062.71. Following the completion of the transaction, the insider now owns 8,063 shares of the company’s stock, valued at $406,617.09. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Zoetis Inc. (NYSE:ZTS) opened at 51.09 on Friday. Zoetis Inc. has a 1-year low of $38.26 and a 1-year high of $53.14. The firm has a 50-day moving average of $50.71 and a 200 day moving average of $49.43. The company has a market capitalization of $25.23 billion, a P/E ratio of 36.83 and a beta of 1.05.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported $0.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.46 by $0.06. The firm earned $1.20 billion during the quarter, compared to analysts’ expectations of $1.22 billion. Zoetis had a net margin of 14.10% and a return on equity of 72.96%. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.50 earnings per share. On average, analysts anticipate that Zoetis Inc. will post $1.93 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Thursday, November 3rd will be paid a $0.095 dividend. The ex-dividend date is Tuesday, November 1st. This represents a $0.38 dividend on an annualized basis and a dividend yield of 0.74%. Zoetis’s dividend payout ratio (DPR) is presently 27.54%.

ZTS has been the subject of a number of recent research reports. Guggenheim reiterated a “buy” rating and issued a $60.00 price objective on shares of Zoetis in a research note on Monday, July 18th. Barclays PLC lifted their price objective on shares of Zoetis from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Thursday, August 4th. Citigroup Inc. boosted their price target on shares of Zoetis from $50.00 to $53.00 and gave the company a “neutral” rating in a research report on Thursday, August 4th. Jefferies Group boosted their price target on shares of Zoetis from $58.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 4th. Finally, Credit Suisse Group AG restated an “outperform” rating and set a $60.00 price target on shares of Zoetis in a research report on Tuesday, August 23rd. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Zoetis currently has an average rating of “Buy” and a consensus price target of $55.92.

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Zoetis by 6.5% in the second quarter. Vanguard Group Inc. now owns 29,819,968 shares of the company’s stock worth $1,415,256,000 after buying an additional 1,812,428 shares during the period. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Zoetis by 7.1% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 12,516,447 shares of the company’s stock worth $650,980,000 after buying an additional 830,200 shares during the period. Independent Franchise Partners LLP boosted its stake in shares of Zoetis by 1.6% in the third quarter. Independent Franchise Partners LLP now owns 11,361,033 shares of the company’s stock worth $590,887,000 after buying an additional 177,286 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Zoetis by 1.3% in the third quarter. Principal Financial Group Inc. now owns 10,016,876 shares of the company’s stock worth $520,978,000 after buying an additional 126,708 shares during the period. Finally, Marshall Wace LLP boosted its stake in shares of Zoetis by 1.9% in the second quarter. Marshall Wace LLP now owns 9,159,978 shares of the company’s stock worth $434,733,000 after buying an additional 173,902 shares during the period. 93.28% of the stock is owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

5 Day Chart for NYSE:ZTS

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.